Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose...
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have...
SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii –...
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND...
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic...
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenzaNEW YORK, Jan....
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer,...
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD...
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
Dr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the RoleST. LOUIS and SAN DIEGO, Jan. 03,...
LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) product image – Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all...
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to...
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median...
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts...